Navigation Links
Pill Reduces Relapses in MS Patients
Date:4/15/2008

First oral drug could benefit many with the autoimmune disease, researchers say

TUESDAY, April 15 (HealthDay News) -- The first pill designed to reduce the number of attacks in people with multiple sclerosis appears to be effective in early tests, Italian researchers report.

The pill was effective in preventing relapses in more than 60 percent of patients who took the pill for three years, according to research that was expected to be presented April 15 the American Academy of Neurology annual meeting, in Chicago.

"All of the current treatments for MS must be injected, so having a pill you can swallow with a glass of water would be a welcome improvement for many people," lead researcher Dr. Giancarlo Comi, from Vita-Salute San Raffaele University in Milan, said in a prepared statement.

In the study, Comi's team treated 281 people with relapsing MS with FTY720 (fingolimod) or a placebo. After six months, two-thirds of the patients who received FTY720 had more than 50 percent fewer relapses, compared with those receiving placebo.

During the three years of the trial, more than 67 percent of the 173 people receiving FTY720 were free of relapses. In addition, 89 percent of the patients were free of disease activity and 75 percent did not develop new lesions or see their lesions enlarge. This was confirmed by MRI scans, the researchers stated.

"The first-line treatments for MS, beta interferon and glatiramer acetate, reduce the relapse rate by only about 30 percent, so this is a significant development for people with MS," Comi said in a statement.

The most commonly reported side effects of FTY720 were headache, flu and cold symptoms.

The drug works by binding to receptors on immune cells, isolating them in the lymph nodes, thereby reducing their ability to cause the damage associated with MS symptoms.

The study was paid for by Novartis Pharma AG, maker of FTY720.

One expert thinks this preliminary data is encouraging, but a lot more needs to be done to prove the drug's effectiveness.

"This is a new drug that has a very strong scientific rationale why it could work," said Dr. John Richert, executive vice president of the National Multiple Sclerosis Society. "Certainly, everything we've seen so far continues to keep us optimistic."

Richert noted that over three years, 77 patients receiving the drug dropped out of the study. "You're left wondering if a more severe adverse event led to the dropouts," he said.

The six-month data where the drug was tested against placebo looks promising, Richert said. "If this turns out to be a safe oral drug that has substantial benefit, that will be very important for many people with MS," he added.

More information

For more on MS, visit the National Multiple Sclerosis Society.



SOURCES: John Richert, M.D., executive vice president, National Multiple Sclerosis Society, New York City; April 15, 2008, presentation, American Academy of Neurology annual meeting, Chicago


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Essential Nutrient Found in Eggs Reduces Risk of Breast Cancer by 24 Percent
2. Essential nutrient found in eggs reduces risk of breast cancer by 24 percent
3. Psychological intervention reduces postembolization pain
4. Aspirin Reduces Asthma Risk Among Older Women
5. Low-Fat Dairy Reduces High Blood Pressure Risk
6. HPV vaccine reduces abnormal pap test results
7. Renal Assist Device reduces risk of death from acute kidney failure
8. Folic Acid in the Food Supply Reduces Birth Defects, but May Cause Extra Cancers, Reports the Harvard Womens Health Watch
9. Restricting kids video time reduces obesity, randomized trial shows
10. Low-intensity exercise reduces fatigue symptoms by 65 percent, study finds
11. Super Prostate Product - More Beta-sitosterol, all-natural Best Prostate(TM) Formula for Enlarged Prostate and BPH - Increases Urine Flow, Reduces Waking and Improves Quality of Life
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pill Reduces Relapses in MS Patients
(Date:3/1/2017)... ... March 01, 2017 , ... ... of eating disorders, is pleased to announce the opening of residential services, in ... this week, Aloria Health will accept adult clients for residential treatment. , ...
(Date:3/1/2017)... , ... March 01, 2017 , ... Hennessey Performance (HPE) today announced its VelociRaptor 600 ... Ford EcoBoost 3.5L twin turbo V6 engine from 450 bhp and 510 lb-ft of torque ... a 0-60 mph time of just 4.2 seconds while running down the ¼ mile in ...
(Date:3/1/2017)... ... March 01, 2017 , ... Both incentives ... Supplemental Nutrition Assistance Program (SNAP) can reduce food insecurity. Findings are presented in ... the American Journal of Preventive Medicine . , Researchers examined data from two ...
(Date:3/1/2017)... ... March 01, 2017 , ... ... the release of its 2017 update to Compass, the popular online learning ... advisors. , Suitable for standardizing both new-hire on-boarding and annual competency-validation, Compass ...
(Date:3/1/2017)... ... 01, 2017 , ... Award-winning medical group Allied Anesthesia today announced that, as ... nations, averaging more than one trip per year since 1998. Char was named the ... features the details of his charitable work. Char has been an Allied Anesthesiologist since ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... Bio-Techne Corporation has partnered with Brazil ... diagnostic tool for the veterinary market. The PARATEST ... the only non-toxic, biodegradable fixative available to the ... Bio-Techne,s Diagnostic Division in Devens, MA ... manufacturing, and packaging capabilities to bring this unique ...
(Date:3/1/2017)... Research and Markets has announced the addition of ... & Infectious Diseases" report to their offering. ... Did you know? - ... Genomic Health, Inc.. - Beijing Wantai Biological Pharmacy,s Beijing ... infectious diseases diagnostics in China . - MDxHealth ...
(Date:3/1/2017)... HOUSTON , March 1, 2017  The Welch ... funding for basic research, today announced that Drs. ... are the 2017 recipients of the Norman ... being recognized as ,rising stars, having contributed significant scientific ... the first time in the 15 years of the ...
Breaking Medicine Technology: